Agenus (AGEN) Tops Q1 EPS by 2c
Get Alerts AGEN Hot Sheet
Revenue Growth %: +35.3%
Financial Fact:
General and administrative: -8.11M
Today's EPS Names:
CPSS, HARL, MCET, More
Join SI Premium – FREE
Agenus (NASDAQ: AGEN) reported Q1 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $15.13 million versus the consensus estimate of $12.35 million.
"We accelerated the development of AGEN1181, advanced our plans to file our BLAs and filed two INDs for our allogeneic iNKT cell therapy to treat cancer and COVID-19," said Garo Armen, Ph.D., Chairman and CEO, Agenus. "Our ability to rapidly enroll in our bali and zali trials, in just 2 years, underscores the speed with which we can advance our AGEN1181 +/- bali and our innovative pipeline of products including allogeneic cell therapy programs."
For earnings history and earnings-related data on Agenus (AGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus Inc. (AGEN) PT Lowered to $35 at Baird
- Rexford Industrial Realty (REXR) Reports In-Line Q1 EPS, provides guidance
- Logansport Financial Corp. (LOGN) Reports Q1 EPS of $0.44
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!